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Relative dose intensity (RDI) of chemotherapy in patients with aggressive 
lymphoma is related to survival outcomes [1]. Development of granulocyte colony-
stimulating factor (G-CSF) has allowed reduction of the interval between 
chemotherapy doses, which in turn may increase tumour cytotoxicity. One such 
‘dose-dense’ regimen for the treatment of aggressive lymphoma is CHOP-14 i.e. 
cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days, 
with the same cumulative dose as standard 21-day CHOP (CHOP-21). The addition 
of rituximab (R), to CHOP-14 improves outcomes compared to CHOP-14 alone [2], 
although the advantage of this regimen over R-CHOP-21 in survival was not 
demonstrated [3]. R-CHOP-14 is currently accepted as a standard of care in the 
treatment of aggressive non-Hodgkin’s lymphoma (NHL) [4], although practices 
vary from country to country. 
Treatment guidelines published by the European Organisation for Research 
and Treatment of Cancer (EORTC) recommend G-CSF support for patients with 
lymphomas or solid tumours receiving a dose-dense regimen, and for 
chemotherapy regimens associated with a risk of febrile neutropenia (FN) at least 
20% [4]. Importantly, FN is associated with increased mortality in patients with NHL 
[5]. In routine clinical practice, however, G-CSF use varies widely and prospective 
studies are still needed to validate the impact of full dose intensity with optimal G-
CSF support.  
We report data on G-CSF use, neutropenia outcomes, and chemotherapy 
delivery among diffuse large B-cell lymphoma (DLBCL) patients who received R-
CHOP-14 in an observational study of patients receiving CHOP-14 or CHOP-21 
with or without rituximab for the treatment of NHL (IMPACT NHL, 
www.clinicaltrials.gov trial number NCT0C903812). 
The study was conducted in 14 European countries and Australia; full details 
of the study design have been published previously [6]. Briefly, centres 
prospectively enrolled 10–20 adult patients (age ≥18 years) diagnosed with NHL, 
whether chemotherapy-naïve or previously treated, who were planned to receive at 
least three chemotherapy cycles. Each study centre also retrospectively enrolled 5–
10 consecutive patients who had completed chemotherapy having been planned for 
least three cycles. The study was conducted in accordance with the principles of the 
Declaration of Helsinki and approved by ethics committees at all participating 
centres. Written informed consent was obtained from all patients (where required). 
Patients were treated between 2005 and 2008. The full analysis set (FAS) 
for each assessment included all patients who started at least one cycle of 
chemotherapy and provided data for that assessment. The primary outcome 
measure was the proportion of patients with an investigator-assessed risk of FN 
≥20% who were planned to receive primary prophylaxis with G-CSF (any daily G-
CSF or pegfilgrastim). Investigator assessment of FN risk was based on 2006 
EORTC guidelines [7]. Primary prophylaxis was defined as first course of G-CSF 
support initiated in days 1–7 of first chemotherapy cycle. FN was defined as a 
single oral temperature ≥38.3 ˚C or a temperature of ≥38.0 ˚C for ≥1 hour with a 
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neutrophil count of <0.5 x 109/L, or <1.0 x 109/L and predicted to fall below 0.5 x 
109/L. [5] Secondary outcome measures included incidence of FN, chemotherapy 
delivery (dose delays >3 days, dose reductions ≥10% in any chemotherapeutic 
agent, and achievement of RDI ≥90%; excluding vincristine, rituximab and 
prednisone). All pre-planned analyses were descriptive in nature. In a post-hoc 
analysis, data were modelled to examine risk factors associated with RDI <90%.  
Age, International Prognostic Index (IPI) score, sex, Ann Arbor stage, bone marrow 
involvement, co-morbidities and whether a patient received G-CSF primary 
prophylaxis were considered for inclusion in the model. Co-morbidities were defined 
as those that were current or continuing from the cardiovascular, respiratory, 
hepatic/biliary or renal system organ classes.  
A total of 1829 patients were included in the FAS; 1136 had DLBCL, of 
whom 409 received R-CHOP-14 and were included in this analysis. Most patients 
were planned for six cycles (n=222; 54%) or eight cycles (n=131; 32%), with 
45 patients (11%) planned for three cycles, 10 patients (2%) for four cycles, and 
one further patient for seven cycles. In total, 357 patients (87%) completed their 
planned number of cycles.  
Baseline demographics of the 409 patients with DLBCL receiving R-CHOP-
14 categorised according to whether or not they received primary G-CSF 
prophylaxis are shown in Table I. Overall, it was difficult to detect a discernable 
pattern in the distribution of observed risk factors for neutropenia between patients 
who received primary prophylaxis and those who did not. Despite EORTC 
guidelines recommending that dose-dense regimens are supported by G-CSF [6,9], 
16% (104/409) of patients administered R-CHOP-14 did not receive primary 
prophylaxis with G-CSF. Of 345 patients who received primary prophylaxis with G-
CSF, 226 (66%) received pegfilgrastim and 119 (34%) received daily G-CSF. The 
median (Q1, Q3) number of doses of daily G-CSF primary prophylaxis per cycle in 
which G-CSF was given was 5.5 (4.0, 7.0). The need for G-CSF support is 
highlighted by the finding that 61 of the 64 patients who were not given G-CSF from 
cycle 1 were subsequently administered G-CSF (secondary prophylaxis, n=56; G-
CSF treatment, n=5). 
Primary prophylaxis was given to 94–98% of patients in the Netherlands, 
Spain and Nordic countries, to 78% of patients in Germany and France, but only to 
58% of patients in Belgium and 47% of patients in Italy. 
Of the 409 DLBCL patients who received R-CHOP-14, 323 (79%) were 
considered high FN risk by investigators. Of these, 84% (270/323) were 
administered primary G-CSF prophylaxis. Overall, FN occurred in 20% of patients 
(n=81), with 6% (n=24) experiencing FN in cycle 1. 
Chemotherapy dose delays >3 days and dose reductions ≥10% occurred in 
47% (95% CI: 41, 52) and 12% (95% CI: 9, 16) of patients who received primary G-
CSF prophylaxis and in 75% (95% CI: 63, 84) and 19% (95% CI: 11, 30) of those 
who did not, respectively. The proportion of patients who achieved ≥90% RDI was 
68% (95% CI: 63, 73) for patients receiving primary prophylaxis and 47% (95% CI: 
Le
uk
 L
ym
ph
om
a 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f Z
ue
ric
h 
on
 1
2/
05
/1
1
Fo
r p
er
so
na
l u
se
 o
nl
y.
JU
ST
 A
CC
EP
TE
D
 
 
4
35, 59) for those not receiving primary prophylaxis (Figure 1). Such RDI reduction 
runs counter to the intention of dose-dense R-CHOP-14, and carries a risk for 
inferior outcome [12]. Furthermore, chemotherapy delivery in the ‘real world’ 
appears to be lower than that recorded in clinical trials. In the RICOVER study, for 
example, median RDI (cyclophosphamide and doxorubicin) was found to be 99% 
for patients receiving six cycles of R-CHOP-14, and 96% for eight cycles of R-
CHOP-14 [2].   
Previous studies have shown that low pre-treatment haematological cell 
counts, female sex, low body weight, poor performance status and elevated LDH 
were generally associated with higher hematotoxicity [4,7,9], while age, 
performance status and lack of G-CSF primary prophylaxis were associated with 
reduced dose delivery [10,11]. Using this list as a basis, we performed a logistic 
regression analysis to identify predictors of RDI <90% (n=364 patients included). 
Variables statistically significant for predicting <90% RDI were higher IPI score (high 
vs low: OR 4.79, 95% CI 2.04-11.23; intermediate vs low OR 1.74, 95% CI 1.00-
3.02; combined p-value=0.0015), absence of G-CSF primary prophylaxis (OR 2.45, 
95% CI 1.28-4.66; P=0.0065), and increased age (OR 1.04, 95% CI 1.02-1.06; 
P=0.001). These variables are consistent with those identified in other published 
models [11,12], indicating they are important factors for clinicians to be aware of 
when considering treatment with R-CHOP-14.  
This observational study is representative of European and Australian 
clinical practice in recent years, although it should be noted that some patients were 
included retrospectively. Furthermore, differences in baseline characteristics 
between patients who did or did not receive primary prophylaxis mean that 
comparisons between these groups must be interpreted with caution.  
In summary, these data provide a useful overview of G-CSF support and 
neutropenia-related outcomes in patients with DLBCL receiving dose-dense 
chemotherapy with R-CHOP-14. Patients who received G-CSF support from cycle 1 
appeared more likely to receive optimal RDI than those who did not. Consistent 
application of guidelines and primary G-CSF prophylaxis may improve 
chemotherapy delivery, which may in turn lead to improved outcomes for patients. 
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Table Legend 
Table I 
Baseline demographics of patients with DLBCL receiving R-CHOP-14, categorized 
according to primary G-CSF prophylaxis 
 
 Primary G-CSF
prophylaxis* 
(n=345) 
No primary G-CSF
prophylaxis 
(n=64) 
All patients 
 
(n=409) 
Age (years), mean (range) 58.1 (18–83) 
 
60.2 (26–87) 58.4 (18–87) 
 
Age, n (%) 
 ≥65 years 
 <65 years 
 
 
137 (40) 
208 (60) 
 
31 (48) 
33 (52) 
 
168 (41) 
241 (59) 
Sex, n (%) 
 Male 
 Female 
 
 
200 (58) 
145 (42) 
 
38 (59) 
26 (41) 
 
238 (58) 
171 (42) 
ECOG performance status, n (%) 
     0–1 
     2–4 
    Missing 
 
312 (90) 
29 (9) 
4 (1) 
 
60 (94) 
2 (3) 
2 (3) 
 
372 (91) 
31 (8) 
6 (1) 
Ann Arbor stage, n (%) 
 1 
     2 
     3 
 4 
     Missing 
 
 
57 (17) 
81 (23) 
84 (24) 
122 (35) 
1 (0) 
 
10 (16) 
16 (25) 
11 (17) 
26 (41) 
1 (2) 
 
67 (16) 
97 (24) 
95 (23) 
148 (36) 
2 (0) 
IPI, n (%) 
 Low 
     Intermediate 
 High 
 Missing 
 
104 (30) 
182 (53) 
30 (9) 
29 (8) 
 
20 (31) 
28 (44) 
6 (9)  
10 (16) 
 
124 (30) 
210 (51) 
36 (9)  
39 (10) 
Bone marrow involvement, n (%) 46 (13) 9 (14) 55 (13) 
 
*First course of G-CSF support initiated in days 1–7 of first chemotherapy cycle 
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Figure Legend 
Figure 1 
Cumulative plot of relative dose intensity for R-CHOP-14 divided for DLBCL 
patients receiving primary prophylaxis and no primary prophylaxis. Dashed lines 
indicate the proportion of patients in each group who failed to acheive an RDI of 
90% (32% receiving primary prophylaxis and 53% not receving primary 
prophylaxis). RDI ≥90% was achieved by 68% of patients reciving primary 
prophylaxis and 47% of those not receiving primary prophylaxis. 
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